No Benefit to Adding Palbociclib to Early Breast Cancer Therapy No Benefit to Adding Palbociclib to Early Breast Cancer Therapy
A phase 3 trial now confirms no benefit to adding palbociclib to endocrine therapy in early HR-positive, HER2-negative breast cancer.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Endocrine Therapy | Health | Hematology | HER2